Programming Algorithm for the Management of Speech Impairment in Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease

Bart E. K. S. Swinnen, Veronia Lotfalla, Marije N. Scholten, Rosanne H. N. Prins, Kelly M. Goes, Stefanie de Vries, Joke J. M. Geytenbeek, Joke M. Dijk, Vincent J. Odekerken, Maarten Bot, Pepijn van den Munckhof, Peter R. Schuurman, Rob M. A. de Bie, Martijn Beudel

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson's disease (PD) has an ambiguous relation to speech. Speech impairment can be a stimulation-induced side effect, and parkinsonian dysarthria can improve with STN-DBS. Owing to the lack of an up-to-date and evidence-based approach, DBS reprogramming for speech impairment is largely blind and greatly relies on the physician's experience. In this study, we aimed to establish an evidence- and experience-based algorithm for managing speech impairment in patients with PD treated with STN-DBS. Materials and Methods: We performed a single-center retrospective study to identify patients with STN-DBS and speech impairment. Onset of speech impairment, lead localization, and assessment of DBS-induced nature of speech impairment were collected. When DBS settings were adjusted for improving speech, the magnitude and duration of effect were collected. We also performed a systematic literature review to identify studies describing the effects of parameter adjustments aimed at improving speech impairment in patients with PD receiving STN-DBS. Results: In the retrospective study, 245 of 631 patients (38.8%) with STN-DBS had significant speech impairment. The probability of sustained marked improvement upon reprogramming was generally low (27.9%). In the systematic review, 23 of 662 identified studies were included. Only two randomized controlled trials have been performed, providing evidence for interleaving-interlink stimulation only. Considerable methodologic heterogeneity precluded the conduction of a meta-analysis. Conclusions: Speech impairment in STN-DBS for PD is frequent, but high-quality evidence regarding DBS parameter adjustments is scarce, and the probability of sustained improvement is low. To improve this outcome, we propose an evidence- and experience-based approach to address speech impairment in STN-DBS that can be used in clinical practice.
Original languageEnglish
JournalNeuromodulation
Early online date2023
DOIs
Publication statusE-pub ahead of print - 2023

Keywords

  • DBS
  • Parkinson's disease
  • dysarthria
  • speech impairment
  • subthalamic nucleus

Cite this